8,200 Shares in Royalty Pharma PLC $RPRX Bought by Viewpoint Investment Partners Corp

Viewpoint Investment Partners Corp purchased a new position in shares of Royalty Pharma PLC (NASDAQ:RPRX) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 8,200 shares of the biopharmaceutical company’s stock, valued at approximately $479,000.

A number of other hedge funds have also added to or reduced their stakes in RPRX. Bank of America Corp DE lifted its stake in Royalty Pharma by 29.0% during the first quarter. Bank of America Corp DE now owns 3,495,846 shares of the biopharmaceutical company’s stock worth $167,696,000 after purchasing an additional 786,921 shares during the last quarter. Amundi boosted its holdings in shares of Royalty Pharma by 15.3% in the 1st quarter. Amundi now owns 3,088,773 shares of the biopharmaceutical company’s stock valued at $148,168,000 after purchasing an additional 409,394 shares in the last quarter. Dorsey Asset Management LLC increased its stake in shares of Royalty Pharma by 0.8% in the 1st quarter. Dorsey Asset Management LLC now owns 2,276,570 shares of the biopharmaceutical company’s stock valued at $109,207,000 after purchasing an additional 17,101 shares during the last quarter. Hsbc Holdings PLC increased its stake in shares of Royalty Pharma by 2,562.2% in the 1st quarter. Hsbc Holdings PLC now owns 1,544,018 shares of the biopharmaceutical company’s stock valued at $74,000,000 after purchasing an additional 1,486,020 shares during the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. increased its stake in shares of Royalty Pharma by 0.4% in the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,273,705 shares of the biopharmaceutical company’s stock valued at $61,100,000 after purchasing an additional 5,661 shares during the last quarter. 54.35% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Royalty Pharma news, EVP Christopher Hite sold 100,000 shares of the business’s stock in a transaction on Tuesday, September 22nd. The shares were sold at an average price of $58.53, for a total transaction of $5,853,000.00. Following the completion of the sale, the executive vice president owned 270,401 shares in the company, valued at approximately $15,826,570.53. The trade was a 27.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marshall Urist sold 4,126 shares of the business’s stock in a transaction dated Monday, October 5th. The stock was sold at an average price of $57.10, for a total transaction of $235,594.60. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 208,252 shares of company stock valued at $12,324,407 in the last 90 days. 18.84% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on RPRX shares. Wall Street Zen cut Royalty Pharma from a “strong-buy” rating to a “buy” rating in a report on Saturday, September 26th. JPMorgan Chase & Co. raised their price objective on Royalty Pharma from $58.00 to $62.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. Bank of America reaffirmed a “buy” rating on shares of Royalty Pharma in a research note on Wednesday, August 5th. Weiss Ratings raised Royalty Pharma from a “buy (b-)” rating to a “buy (b)” rating in a research note on Monday, September 14th. Finally, TD Cowen boosted their target price on Royalty Pharma from $65.00 to $68.00 and gave the stock a “buy” rating in a research note on Tuesday, September 8th. Eight equities research analysts have rated the stock with a Buy rating. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $61.57.

Royalty Pharma Trading Up 1.4%

RPRX opened at $64.76 on Tuesday. The company has a debt-to-equity ratio of 0.88, a current ratio of 2.80 and a quick ratio of 2.80. Royalty Pharma PLC has a fifty-two week low of $35.92 and a fifty-two week high of $65.35. The firm has a market capitalization of $37.24 billion, a price-to-earnings ratio of 44.66, a PEG ratio of 1.75 and a beta of 0.42. The company’s 50 day moving average price is $59.84 and its two-hundred day moving average price is $52.62.

Royalty Pharma (NASDAQ:RPRX) last posted its quarterly earnings data on Wednesday, August 5th. The biopharmaceutical company reported $1.32 earnings per share for the quarter, beating analysts’ consensus estimates of $1.27 by $0.05. The business had revenue of $674.14 million during the quarter, compared to the consensus estimate of $758.93 million. Royalty Pharma had a return on equity of 30.01% and a net margin of 32.14%. As a group, research analysts predict that Royalty Pharma PLC will post 5.29 earnings per share for the current year.

Royalty Pharma Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be issued a dividend of $0.2350 per share. The ex-dividend date is Friday, November 13th. This represents a $0.94 annualized dividend and a dividend yield of 1.5%. Royalty Pharma’s payout ratio is currently 64.83%.

Royalty Pharma Profile

Royalty Pharma plc (NASDAQ:RPRX) is a biopharmaceutical royalty investment company that provides funding to life sciences companies, academic institutions, and other organizations in exchange for rights to future payments tied to approved or development-stage medicines. Its business model gives innovators access to capital while allowing Royalty Pharma to participate in the long-term commercial success of pharmaceutical products.

The company acquires and manages royalty interests across a broad range of therapeutic areas, including immunology, oncology, neuroscience, rare diseases, and infectious diseases.